EX-10.12



 Exhibit 10.12 
 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a
request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and GENOPAVER, LLC, a Delaware limited liability company having a place of business at 2875 South Ocean Boulevard, Suite 214, Palm
Beach, FL 33480 (“Genopaver”). Intrexon and Genopaver may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 
 WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and
DNA vectors, and the control of peptide expression; and 
 WHEREAS, Genopaver now desires
to become Intrexon’s exclusive channel collaborator with respect to such technology for the purpose of developing Genopaver Products (as defined herein), and Intrexon is willing to appoint Genopaver as a channel collaborator in the Field (as
defined herein, and subject to amendments to the definition as permitted herein) under the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS 
 As used in this Agreement, the following capitalized terms shall have the following meanings: 
 1.1 “Active Pharmaceutical Ingredient” means a compound, whether naturally occurring, chemically synthesized, or biologically produced, that is regulated as a drug by the FDA.

 1.2 “Affiliate” means, with respect to a particular Party, any other person or entity that directly
or indirectly controls, is controlled by, or is in common control with such Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms “controlled by” and “under common control
with”) means the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or
policies of an entity, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of Intrexon or Genopaver, and neither Party shall be deemed to
be an Affiliate of the other Party. In addition, any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon or Genopaver solely because it and Intrexon are under common control by Randal J. Kirk or by
investment funds managed by Third Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon or Genopaver. 








 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 1.3 “Alkaloid” means the compounds, commonly referred to as true
alkaloids, that contain a nitrogen heterocycle and originate from amino acids included in the following classes of compounds: pyrrolidine derivatives, tropane derivatives, pyrrolizidine derivatives, piperidine derivatives, quinolizidine derivatives,
indolizidine derivatives, pyridine derivatives, isoquinoline derivatives, oxazole derivatives, isoxazole derivatives, thiazone derivatives, quinazoline derivatives, acridine derivatives, quinoline derivatives, indole derivatives, imadazole
derivatives, and purine derivatives. 
 1.4 “Alkaloid Program” means the channel collaboration between
the Parties as established and governed by this Agreement. 
 1.5 “Applicable Laws” has the meaning set
forth in Section 8.2(d)(xii). 
 1.6 “Authorizations” has the meaning set forth in
Section 8.2(d)(xii). 
 1.7 “CC” has the meaning set forth in Section 2.2(b). 

1.8 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.9 “Claims” has the meaning set forth in Section 9.1. 

1.10 “CMCC” has the meaning set forth in Section 2.2(b). 

1.11 “Committees” has the meaning set forth in Section 2.2(a). 

1.12 “Commercialize” or “Commercialization” means any activities directed to marketing,
promoting, distributing, importing for sale, offering to sell and/or selling Genopaver Products. 
 1.13
“Commercial Sale” means for a given product and country the sale for value of that product by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if
necessary) has been obtained for such product in such country. 
 1.14 “Complementary In-Licensed Third Party
IP” has the meaning set forth in Section 3.8(a). 
 1.15 “Confidential Information” means
each Party’s confidential Information, disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties, regardless of whether in oral, written, graphic or electronic form. 

1.16 “Control” means, with respect to Information, a Patent or other intellectual property right, that a Party
owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party.


  
 2 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 1.17 “Costs of Goods Sold” or “COGS” means all
Manufacturing Costs that are directly and reasonably attributable to manufacturing of an Genopaver Product in accordance with US GAAP for commercial sale in the countries where such Genopaver Product has been launched. 

1.18 “Diligent Efforts” means, with respect to a Party’s obligation under this Agreement, the level of
efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Genopaver Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the
Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts
requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation. 

1.19 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 

1.20 “Executive Officer” means : (a) the Chief Executive Officer of the applicable Party, or
(b) another senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (i) a Committee dispute, provided that such appointed
officer is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (ii) a dispute described in Section 11.1. 

1.21 “FDA” has the meaning set forth in Section 8.2(d)(xii). 

1.22 “Field” means the fermentative production of Alkaloids through genetically modified cell-lines and substrate
feeds for use as Active Pharmaceutical Ingredients or as commercially-sold intermediates in the manufacture of Active Pharmaceutical Ingredients. The Field specifically excludes the use of Alkaloids for the manufacture of diacylhydrazines or any
other molecule that controls an ecdysone-based switch. For clarity, the Field does not include the production of Alkaloids in genetically modified whole plants. 
 1.23 “Field Infringement” has the meaning set forth in Section 6.3(b). 
 1.24 “Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good,
product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Section 4.5, Intrexon will bill for its internal direct costs incurred through the use of annualized
standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good, product or service. Intrexon may, from time to time, adjust such full-time equivalent
rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide Genopaver with reasonable documentation indicating the basis for any direct and indirect
charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

  
 3 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 1.25 “Genopaver Indemnitees” has the meaning set forth in
Section 9.1. 
 1.26 “Genopaver Product” means any product in the Field that is created, produced,
developed, or identified in whole or in part, directly or indirectly, by or on behalf of Genopaver during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials. 

1.27 “Genopaver Program Patent” has the meaning set forth in Section 6.2(b). 

1.28 “Genopaver Termination IP” means all Patents or other intellectual property that Genopaver or any of its
Affiliates Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the development, manufacture or Commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field.

 1.29 “Gross Profit” means, with respect to sales of a particular product by a seller who is the
producer of such product, the gross revenues derived by that seller or an Affiliate of that seller (including without limitation net sales of the product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee),
as determined in accordance with US GAAP as the gross amount invoiced on account of sales of the product less COGS as determined in accordance with US GAAP. In the case of any sale for value, such as barter or counter-trade other than in an
arm’s length transaction exclusively for cash, Gross Profit shall be deemed to be the net sales at which substantially similar quantities of the product are sold for cash in an arm’s length transaction in the relevant country. If an
Genopaver Product is sold to any Third Party together with other products or services, the price of such product, solely for purposes of the calculation of Gross Profit, shall be deemed to be no less than the price at which such product would be
sold in a similar transaction to a third party not also purchasing the other products or services. 
 1.30
“In-Licensed Program IP” has the meaning set forth in Section 3.8(a). 
 1.31
“Information” means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications,
formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and regulatory test data, analytical and quality control data, stability data, studies and
procedures, and patent and other legal information or descriptions. 
 1.32 “Infringement” has the
meaning set forth in Section 6.3(a). 
 1.33 “Intrexon Channel Technology” means Intrexon’s
current and future technology directed towards the design, identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and
specifically including without limitation the following of Intrexon’s 

  
 4 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
platform areas and capabilities: (1) UltraVector®,
(2) LEAPTM, (3) DNA and RNA MOD engineering,
(4) protein engineering, (5) transcription control chemistry, (6) genome engineering, and (7) cell system engineering. 
 1.34 “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 
 1.35 “Intrexon IP” means the Intrexon Patents and Intrexon Know-How. 
 1.36 “Intrexon Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is
reasonably required or useful for Genopaver to conduct the Alkaloid Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the Channel-Related Program IP. 

1.37 “Intrexon Materials” means the genetic code and associated amino acids and gene constructs, in each case
that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in
each case that are reasonably required or provided to Genopaver by or on behalf of Intrexon to conduct the Alkaloid Program. 

1.38 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or
during the Term; and (b) are reasonably required or useful for Genopaver to conduct the Alkaloid Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

1.39 “Intrexon Trademarks” means those trademarks related to the Intrexon Channel Technology that are established
from time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.40
“Inventions” has the meaning set forth in Section 6.1(b). 
 1.41 “IPC” has
the meaning set forth in Section 2.2(b). 
 1.42 “JSC” has the meaning set forth in
Section 2.2(b). 
 1.43 “Losses” has the meaning set forth in Section 9.1. 

1.44 “Manufacturing Costs” means, with respect to a given Genopaver Product, the full-time equivalent costs (under a
reasonable accounting mechanism to be agreed upon by the Parties) and out-of-pocket costs that Genopaver or any of its Affiliates incurred in manufacturing such products, including costs and expenses incurred in connection with (a) the
development or validation of any manufacturing process, formulations or delivery systems, or improvements to the foregoing; (b) manufacturing scale-up; (c) in-process testing, stability testing and release testing; (d) quality
assurance/quality control development; (e) internal and Third Party costs and expenses incurred in connection with qualification and validation of Third Party contract manufacturers, including scale up, process and equipment validation, and
initial manufacturing 

  
 5 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
licenses, approvals and inspections; (f) packaging development and final packaging and labeling; (g) shipping configurations and shipping studies; and (h) overseeing the conduct of
any of the foregoing. “Manufacturing Costs” shall further include: (i) to the extent that any such Genopaver Product is manufactured by a Third Party manufacturer, the out-of-pocket costs incurred by Genopaver or any of its Affiliates
to the Third Party for the manufacture and supply (including packaging and labeling) thereof, and any reasonable out-of-pocket costs and direct labor costs incurred by Genopaver or any of its Affiliates in managing or overseeing the Third Party
relationship determined in accordance with the books and records of such Party or its Affiliates maintained in accordance with US GAAP; and (ii) to the extent that any such Genopaver Product is manufactured by Genopaver or any of its
Affiliates, direct material and direct labor costs attributable to such product, as well as reasonably allocable overhead expenses, determined in accordance with the books and records of Genopaver or its Affiliates maintained in accordance with US
GAAP. 
 1.45 “Patents” means (a) all patents and patent applications (including provisional
applications), (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and
the like of the foregoing, and (c) any foreign or international equivalents of any of the foregoing. 
 1.46
“Permitted Ancillary Commercial Use” means the commercial use or sale, for a purpose other than as Active Pharmaceutical Ingredients or as commercially-sold intermediates in the manufacture of Active Pharmaceutical Ingredients,
of any Alkaloid-containing product that is produced under the Alkaloid Program or otherwise created, produced, developed, or identified in whole or in part, directly or indirectly, by or on behalf of Genopaver during the Term through use or practice
of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials. For example, Genopaver may elect to sell or commercially use, but is not obligated to sell or commercially use, a Genopaver Product that was developed as an Active
Pharmaceutical Ingredient for a Permitted Ancillary Commercial Use outside the Field, such as for use as, and subject to Section 3.8(g), (i) a food supplement, (ii) an industrial chemical unrelated in purpose to the synthesis of
Active Pharmaceutical Ingredients, or (iii) a food additive. 
 1.47 “Product-Specific Program
Patent” means any issued Intrexon Patent where all the claims are directed to Inventions that relate solely and specifically to Genopaver Products. In the event of a disagreement between the Parties as to whether a particular Intrexon
Patent is or is not a Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration
pursuant to Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program
Patent or (b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 
 1.48 “Product Sublicense” has the meaning set forth in Section 3.2(c). 

  
 6 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 1.49 “Product Sublicensee” has the meaning set forth in
Section 3.2(c). 
 1.50 “Proposed Terms” has the meaning set forth in Section 11.2.

 1.51 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 

1.52 “RAC” has the meaning set forth in Section 2.2(b). 

1.53 “Recovery” has the meaning set forth in Section 6.3(f). 

1.54 “Retained Product” has the meaning set forth in Section 10.4(a). 

1.55 “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.56 “SEC” means the United States Securities and Exchange Commission. 

1.57 “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration,
regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Genopaver or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or
Commercialize Genopaver Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration for a
grant of equity of Genopaver to the extent that such consideration is equal to or less than fair market value (i.e., any amounts in excess of fair market value shall be Sublicensing Revenue); and (c) amounts received from sublicensees in
respect of any Genopaver Product sales or uses that are included in the calculation of revenue sharing payments made to Intrexon under Sections 5.2(a) or 5.2(b). 
 1.58 “Superior Product” means a product produced by fermentation in the Field that, based on the data then available, (a) demonstrably appears to offer either superior yield
or safety or significantly lower cost of production, as compared with both (i) those products that are marketed (either by Genopaver or others) at such time for similar commercial use and (ii) those products that are being actively
developed by Genopaver for such purpose; (b) demonstrably appears to represent a substantial improvement over such existing products; and (c) has intellectual property protection and a regulatory approval pathway that, in each case, would
not present a significant barrier to commercial development. 
 1.59 “Supplemental In-Licensed Third Party
IP” has the meaning set forth in Section 3.8(a). 
 1.60 “Support Memorandum” has the
meaning set forth in Section 11.2. 
 1.61 “Technology Access Fee” for the purposes of this
Agreement has the meaning as set forth in Section 5.1. 
 1.62 “Term” has the meaning set forth in
Section 10.1. 

  
 7 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 1.63 “Territory” means the world. 

1.64 “Third Party” means any individual or entity other than the Parties or their respective Affiliates. 

1.65 “Third Security” means Third Security, LLC. 

1.66 “US GAAP” means generally accepted accounting principles in the United States. 

ARTICLE 2 

SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 

2.1 Scope. 
 (a) Generally. The general purpose of the Alkaloid Program described in this Agreement will be to use the Intrexon Channel Technology to research, develop and Commercialize Genopaver Products. As
provided below, the JSC shall establish, monitor, and govern projects for Genopaver Products. Either Party may propose other potential projects in the Field for review and consideration by the JSC. 

2.2 Committees. 
 (a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to oversee the Alkaloid Program and to facilitate communications between the Parties
with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the obligation to exercise its authority consistent with the respective purpose for such
Committee as stated herein and any such decisions shall be made in good faith. 
 (b) Formation and Purpose. Promptly
following the Effective Date, the Parties shall confer and then create the JSC and the IPC, and, optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the
extent that after conferring both Parties agree to not create a Committee (other than the JSC and the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred
Committee, at which point the Parties will thereafter promptly create the so-deferred Committee. 
  

			
	 Committee
	  	 Purpose

	Joint Steering Committee (“JSC”)	  	Establish projects for the Alkaloid Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans. The JSC shall
establish budgets not less than on a quarterly basis.


  
 8 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  


			
	 Committee
	  	 Purpose

	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Alkaloid Program.
		
	Regulatory Approval Committee (“RAC”)	  	Review and approve all research and development plans and projects associated with any necessary regulatory approvals, all associated publications, and all regulatory filings and
correspondence relating to gaining regulatory approval under the Alkaloid Program; and review and approve itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for Commercialization activities under the Alkaloid Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate intellectual property issues in connection with the Alkaloid Program; review and approve itemized budgets with respect to the foregoing.

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed three
(3) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the representatives
must all be employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if :(i) such non-employee representative agrees in
writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party consents to the designation of such non-employee representative, which
consent shall not be unreasonably withheld. For purposes of this Section 2.3, employees of Third Security may, at Genopaver’s election, serve as members of a Committee as if they were employees of Genopaver. Each representative as
qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party. Each Committee shall
have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall alternate between the Parties, with Genopaver selecting the
chairperson first for 

  
 9 









 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
the JSC, RAC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling meetings, preparing and circulating an
agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 
 (b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than once every six (6) months, with the
caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the so-suspended Committee, at which point the Parties will
thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent that a
Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Genopaver selecting the first meeting location for each Committee. A reasonable number of additional representatives of
a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an Intrexon employee or agent serving on a Committee shall not prevent
Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing support services as set forth in Section 4.5 below. 

(c) Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate information at least three
(3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a
specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting. 

(d) Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder or
from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any power to amend this Agreement.
Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. Additionally, no member of any Committee shall be able to vote in such Committee and thereby bind its respective Party on any
material matter accept as otherwise properly authorized, approved, or delegated by such Party in accord with Section 2.5. 

2.4 Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter within thirty
(30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or
by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such
dispute is not resolved by the Executive Officers 

  
 10 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
within thirty (30) days after submission of such dispute to such Executive Officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the
authority to finally resolve such dispute acting in good faith. 
 (a) Casting Vote at JSC. If a dispute at the JSC is
not resolved pursuant to Section 2.4 above, then the Executive Officer of Genopaver shall have the authority to finally resolve such dispute. 
 (b) Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture
of an Genopaver Product through the use of Intrexon Channel Technology or Intrexon IP, or the manufacturing of other components of Genopaver Products contracted for or manufactured by Intrexon or reasonable controls regarding the dissemination of
Intrexon Technology, Intrexon IP or Intrexon Materials, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of Genopaver shall have the
authority to finally resolve such dispute. 
 (c) Casting Vote at RAC. If a dispute at the RAC is not resolved pursuant
to Section 2.4 above, then the Executive Officer of Genopaver shall have the authority to finally resolve such dispute. 

(d) Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of
Genopaver shall have the authority to finally resolve such dispute. 
 (e) Casting Vote at IPC. If a dispute at the IPC
is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program
Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 
 (f) Other Committees. If any additional Committee or subcommittee other than those set forth in Section 2.2(b) is formed, then the Parties shall, at the time of such formation, agree on which
Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 
 (g)
Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this
Agreement; (ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute
involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is
inconsistent with applicable law. 
 2.5 Authorization of Committee Representatives. Each representative serving on a
Committee shall be responsible for ensuring that he or she acts only as duly authorized by its 

  
 11 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any Committee votes. Any Committee representative
shall only be able to bind its respective appointing Party via any Committee vote or other material Committee activity to the extent such vote or other activity has been previously approved by the Party, is within the authority duly delegated to the
representative by the respective Party, or is otherwise authorized by its respective Party as may be required by that Party’s corporate charter or bylaws, or by its board of directors. Any action or vote taken without valid authority shall be
considered null and void and shall be without effect unless subsequently approved by a vote in accord with this Section 2.5. 
 ARTICLE 3 
 LICENSE GRANTS 

3.1 Licenses to Genopaver. 
 (a) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Genopaver a license under the Intrexon IP to research, develop, use, make, have made, sell, and offer for sale
Genopaver Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any development, selling, offering for sale or other Commercialization of Genopaver Products in the Field, and shall be otherwise
non-exclusive. 
 (b) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Genopaver a
non-exclusive, royalty-free license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of Genopaver Products in the promotional materials, packaging, and labeling for Genopaver Products, as provided under and
in accordance with Section 4.7. 
 (c) Subject to the restrictions of Section 3.8(g) and the other terms and
conditions of this Agreement, Intrexon hereby grants to Genopaver a non-exclusive license under the Intrexon IP to use, make, have made, sell, and offer for sale Genopaver Products for Permitted Ancillary Commercial Uses in the Territory.

 3.2 Sublicensing. Except as provided in this Section 3.2, Genopaver shall not sublicense the rights granted under
Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Genopaver Products or use or display the Intrexon Trademarks, in
each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, Genopaver (and its Product Sublicensees only to the extent explicitly set forth in
Section 3.2(a) below) shall have a limited right to sublicense under the circumstances described in Sections 3.2(a) through 3.2(c). 
 (a) Genopaver may transfer, to the extent reasonably necessary and after providing Intrexon with reasonable advance notice thereof, Intrexon Materials that are or express Genopaver Products to a
Third Party contractor performing contract manufacturing 

  
 12 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
responsibilities for Genopaver Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Genopaver transfers any
Intrexon Materials under this Section 3.2(a), Genopaver will remain obligated to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated
by any such Third Party contractor. A Product Sublicensee of Genopaver may transfer, to the extent reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, Intrexon Materials that are or express
ingredients for the Genopaver Product sublicensed by the Product Sublicensee to a Third Party contractor performing on behalf of that Product Sublicensee contract manufacturing responsibilities for Genopaver Products, and may in connection therewith
grant limited sublicenses to the extent necessary to enable such Third Party to perform such activities. Genopaver will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such
Product Sublicensee, after obtaining Intrexon’s consent, will take commercially reasonable steps, including contractually obligating any such Third Party contractors, to ensure that the rights of Intrexon in and to the Intrexon Materials and
Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any Third Party contractors of such Product Sublicensees. 
 (b) Genopaver may, with Intrexon’s written consent, which consent shall not be unreasonably withheld, sublicense the rights granted under Section 3.1 to an Affiliate, or transfer the
Intrexon Materials to an Affiliate, or grant an Affiliate the right to display the Intrexon Trademarks. In the event that Intrexon consents to any such grant or transfer to an Affiliate, Genopaver shall remain responsible for, and be guarantor of,
the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such performance (as though such Affiliate were Genopaver), including any payment obligations owed to Intrexon
hereunder. 
 (c) Genopaver may grant a sublicense of the rights granted under Section 3.1 (and not including a
right to sublicense under this Section 3.1(c)) to a Third Party licensee of any Genopaver Product (a “Product Sublicensee”) to the extent necessary to permit such Third Party to research, develop, use, import, export, make,
have made, sell, and offer for sale that Genopaver Product (a “Product Sublicense”), provided, that (i) such Product Sublicense is expressly limited to the appropriate Genopaver Product, (ii) such Product Sublicense does
not grant the Product Sublicensee any rights to Intrexon IP other than as incorporated into the Genopaver Product at the time of the Product Sublicense, (iii) such Product Sublicense does not purport to relieve Genopaver of any of its
obligations under this Agreement, (iv) the Product Sublicensee agrees in writing, in a document in form reasonably acceptable to Intrexon and to which Intrexon is an express third party beneficiary, to abide by the following provisions of this
Agreement: Sections 3.1, 3.3-3.5, 3.7, 3.9, and 3.10 and Articles 6, 7, and 10), and (v) the Product Sublicense is presented in full to the JSC by Genopaver before execution by Genopaver and the prospective Product Sublicensee and as soon as is
reasonably practical for the purpose of allowing the JSC to review and comment upon the terms and scope of the Product Sublicense agreement before execution. 
 3.3 Limitation on Sublicensees. None of the enforcement rights under the Intrexon Patents that are granted to Genopaver pursuant to Section 6.3 shall be transferred to, or exercised by, a
sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole discretion. 

  
 13 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 3.4 No Non-Permitted Use. Genopaver hereby covenants that it shall not, nor shall
it permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement.

 3.5 Exclusivity. Neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials
available to any Third Party for the purpose of developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate)
the research, development or Commercialization of any product for purpose of commercial use or sale in the Field, outside of the Alkaloid Program. Further, neither Genopaver nor its Affiliates shall pursue (either by itself or with a Third Party or
Affiliate) outside of the Alkaloid Program the research, development or Commercialization of any product for purpose of commercial use or sale in the Field where such products would compete with Genopaver Products. 

3.6 No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent
Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Genopaver acknowledges
that (i) Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any genetic materials used in an Genopaver Product), and Intrexon IP available to Third Party channel
partners or collaborators for use in fields outside the Field, and (ii) Intrexon has all rights, in Intrexon’s sole discretion, to grant to other channel collaborators and/or Third Parties exclusive and/or non-exclusive rights outside the
Field under the Intrexon IP with respect to the use of the Alkaloids, which grants may restrict or prohibit Genopaver’s previously-permitted activities with respect to Permitted Ancillary Commercial Uses in accord with Sections 3.1(c) and
3.8(g). 
 3.7 Rights to Regulatory Data. Genopaver shall own and control all regulatory data and regulatory filings
relating to Commercialization of Genopaver Products (except to the extent such become Reverted Products). Genopaver shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon at Intrexon’s written request full
copies of all regulatory data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Genopaver Products. To the extent that there exist any regulatory data and reports, regulatory
filings, and communications from regulatory authorities owned by Genopaver (or a Product Sublicensee) that relate both to Genopaver Products and other products produced by Genopaver (or a Product Sublicensee) outside the Field, upon Intrexon’s
written request Genopaver shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon copies of the portions of such data, reports, filings, and communications that relate to Genopaver Products. Subject to its ongoing
obligations of exclusivity under Section 3.5, Intrexon shall be permitted, directly or in conjunction with or through partners or other channel collaborators, to reference this data, reports, filings, and communications relating to Genopaver
Products in regulatory filings made to obtain regulatory 

  
 14 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
approval for products for use in fields outside the Field. Intrexon shall have the right to use any such information in developing and Commercializing products outside the Field and to license
any Third Parties to do so. Notwithstanding the provisions of this Section 3.7, Intrexon shall not, outside of the Alkaloid Program, utilize knowingly any Genopaver data or reports in support of obtaining regulatory approval for a product for
use in the Field. 
 3.8 Third Party Licenses. 
 (a) [*****] shall obtain [*****] any licenses from Third Parties that are required in order to practice the Intrexon Channel Technology in the Field where the licensed intellectual property is
reasonably necessary for Intrexon to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Alkaloid Program (but specifically excluding intellectual property directed to any specific target genes,
active pharmaceutical ingredients or chemical intermediates thereof, or processes or methods for commercially manufacturing Genopaver Products) (“Supplemental In-Licensed Third Party IP”). Other than with respect to Supplemental
In-Licensed Third Party IP, [*****] shall be solely responsible for obtaining [*****] any licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import
Genopaver Products (“Complementary In-Licensed Third Party IP”). Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed Program IP”.

 (b) In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP
or Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Genopaver Products and to the Field. As provided above in
Section 3.8(a), [*****] shall have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third
Party IP at any time, provided that [*****] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against
[*****] or its Affiliates or threatens to bring such action (to the extent such threats would reasonably be considered to subject the Third Party owner or licensee to declaratory judgment jurisdiction) and, after written notice to [*****] of such
action, [*****] fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within ninety (90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed Third Party IP,
subject to Section 3.8(c), [*****] shall have the right to pursue a license under Complementary In-Licensed Third Party IP [*****]. For the avoidance of doubt, [*****] may at any time obtain a license under Complementary In-Licensed Third Party
IP outside the Field [*****] provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with [*****]. 

(c) [*****] shall provide the proposed terms of any license under Complementary In-Licensed Third Party IP and the final version
of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments thereto in good faith. To the


  
 15 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
extent that [*****] obtains a license under Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license agreement for such Supplemental In-Licensed
Third Party IP to the IPC. Notwithstanding the foregoing, [*****] shall not be required to provide drafts or an unexecuted version of a definitive license agreement with respect to Complementary In-Licensed Third Party IP if and to the extent that
(i) doing so would result in a loss of the protections granted under Fed. R. Evid. 408, and (ii) the Parties after duly consulting with one another have not executed a suitable common legal interest or other agreement to prevent such loss
of protections. If [*****] acquires rights under any In-Licensed Program IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be exclusive. Any
Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.8 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity,
(i) any costs incurred by [*****] in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to
Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [*****]. 
 (d) For any Third Party license under which Genopaver or its Affiliates obtain a license under Patents claiming inventions or know-how specific to or used or incorporated into the development,
manufacture, and/or Commercialization of Genopaver Products, Genopaver shall use commercially reasonable efforts to ensure that Genopaver will have the ability, pursuant to Section 10.4(h), to assign such agreement to Intrexon or grant a
sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 
 (e) The licenses granted to
Genopaver under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license
agreement, subject to the cost allocation set forth in Section 3.8(c), provided that Intrexon shall either provide unredacted copies of such upstream license agreements to Genopaver or shall disclose in writing to Genopaver all of
such terms and conditions that are applicable to Genopaver. Genopaver shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Genopaver as
provided in the preceding sentence. 
 (f) If either Party receives notice from a Third Party concerning activities of a
Party taken in conjunction with performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the
receiving Party shall inform the other party thereof within five (5) business days. 
 (g) Intrexon may notify
Genopaver from time to time that it has, as expressly permitted under Section 3.6, entered into a definitive commercial agreement with a Third Party, including with another channel collaborator, which agreement involves the use of Alkaloids
outside of the Field. To the extent that such commercial agreement with the Third Party grants exclusive rights under or to the Intrexon IP, and to the extent that Genopaver’s activities 


  
 16 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
otherwise permitted under Section 3.1(c) could or does overlap with those exclusive rights granted to the Third Party, Genopaver’s rights under Section 3.1(c) upon such notice
shall be automatically and immediately restricted such that Genopaver would no longer be licensed under the Intrexon IP to make, use, sell, or offer for sale the Genopaver Products for any Permitted Ancillary Commercial Uses that would conflict with
the exclusive rights so-granted to the Third Party. Any notice by Intrexon under this Section 3.8(f) will explain with sufficient detail the scope of rights granted to any such Third Party and the effective date and term of such rights to
permit Genopaver to assess the scope of such restriction hereunder, and will identify any significant prior Genopaver activities known to Intrexon that were previously permitted under Section 3.1(c) but that would thereafter be prohibited by
operation of this Section 3.8(g) and such notice. Nothwithstanding the foregoing, Genopaver will be give sixty (60) days from receipt of any such notice under this Section 3.8(g) to sell, use, or otherwise dispose of any inventory
(including for Permitted Ancillary Commercial Uses) affected by such notice. 
 3.9 Licenses to Intrexon. Subject to the
terms and conditions of this Agreement, Genopaver hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by Genopaver or its Affiliates, solely
to the extent necessary for Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon subcontractors as permitted in accord with
Section 4.5 in conjunction with support services (subject to JSC research plan approval). 
 3.10 Restrictions
Relating to Intrexon Materials. Genopaver and its permitted sublicensees shall use the Intrexon Materials solely for purposes of the Alkaloid Program and not for any other purpose without the prior written consent of Intrexon. With respect to
the Intrexon Materials comprising Intrexon’s vector assembly technology, Genopaver shall not, and shall ensure that Genopaver personnel and permitted sublicensees do not, except as otherwise permitted in this Agreement (a) distribute,
sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such
Intrexon Materials or in any way attempt to reverse engineer or sequence such Intrexon Materials.  
 ARTICLE 4

 OTHER RIGHTS AND OBLIGATIONS 

4.1 Development and Commercialization. Subject to Section 4.5, Genopaver shall be solely responsible for the development and
Commercialization of Genopaver Products. Genopaver shall be responsible for all costs incurred in connection with the Alkaloid Program except that Intrexon shall be responsible for the following: (a) costs of basic research with respect to the
Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.5 or research requested by the JSC for the development of a Genopaver Product (which
research costs shall be reimbursed by Genopaver); (b) [*****]; and (c) costs of filing, prosecution and maintenance of Intrexon Patents. 

  
 17 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 4.2 Information and Reporting. Genopaver will keep Intrexon informed about
Genopaver’s efforts to develop and Commercialize Genopaver Products, including reasonable and accurate summaries of Genopaver’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including
regulatory plans, marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Genopaver
Products, including initiation or completion of a regulatory trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, product safety event, receipt of
regulatory approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.7 above, Genopaver shall also provide to Intrexon copies of all final regulatory documents and reports. Intrexon will keep
Genopaver informed about Intrexon’s efforts to undertake discovery-stage research for the Alkaloid Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord
with Section 4.1 above, such disclosures by Genopaver and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Genopaver Products are being developed or Commercialized
anywhere in the world, and shall be reflected in the minutes of such meetings. 
 4.3 Regulatory Matters. At all times
after the Effective Date, Genopaver shall own and maintain, at its own cost, all regulatory filings and regulatory approvals for Genopaver Products that Genopaver is developing or Commercializing pursuant to this Agreement. As such, Genopaver shall
be responsible for reporting all adverse events related to such Genopaver Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that
Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon Materials outside of the Field, Intrexon may request that Genopaver and Intrexon establish and execute a separate safety data exchange agreement, which
agreement will address and govern the timely exchange of safety information generated by Genopaver, Intrexon, and relevant third parties with respect to specific Intrexon Materials. 

4.4 Diligence. 
 (a) Genopaver shall use, and shall require its sublicensees to use, Diligent Efforts to develop and Commercialize Genopaver Products. 

(b) Without limiting the generality of the foregoing, Intrexon may, from time to time, notify Genopaver that it believes it has
identified a Superior Product, and in such case Intrexon shall provide to Genopaver its then-available information about such product and reasonable written support for its conclusion that the product constitutes a Superior Product. Genopaver shall
have the following obligations with respect to such proposed Superior Product: (i) within sixty (60) days after such notification, Genopaver shall prepare and deliver to the JSC for review and approval a development plan detailing how
Genopaver will pursue the Superior Product (including a proposed budget); (ii) Genopaver shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, Genopaver shall use
Diligent Efforts to pursue the development of the Superior Product under the Alkaloid 

  
 18 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
Program in accordance with such development plan. If Genopaver fails to comply with the foregoing obligations, or if Genopaver unreasonably exercises its casting vote at the JSC to either
(x) prevent the approval of a development plan for a Superior Product; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that is insufficient in
view of the nature and magnitude of the opportunity presented by the Superior Product, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth therein). For clarity, any dispute arising
under this 4.4, including any dispute as to whether a proposed project constitutes a Superior Product (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11. 

(c) The activities of Genopaver’s Affiliates and any permitted sublicensees shall be attributed to Genopaver for the purposes
of evaluating Genopaver’s fulfillment of the obligations set forth in this Section 4.4. 
 4.5 Support
Services. The JSC will meet promptly following the Effective Date and establish a plan under which Intrexon will provide support services to Genopaver for the research and development of Genopaver Products under the Alkaloid Program, which
initial plan may be amended from time to time by the JSC. Genopaver will compensate Intrexon for such support services with cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. Additionally, from time to time,
on an ongoing basis, Genopaver shall request, or Intrexon may propose, that Intrexon perform certain additional support services with respect to researching and developing new Genopaver Products or improving the manufacturing or processing methods
for any existing Genopaver Products. To the extent that the Parties mutually agree that Intrexon should perform such additional services, the Parties shall negotiate in good faith the terms under which services would be performed, it being
understood that Intrexon would be compensated for such services by cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. 
 4.6 Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates, (sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines
applicable to the Alkaloid Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials and Genopaver Products. 
 4.7 Trademarks and Patent Marking. To the extent permitted by applicable law and regulations, Genopaver shall ensure that the packaging, promotional materials, and labeling for Genopaver Products,
as appropriate, shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to Genopaver’s reasonable approval of the size, position, and location thereof. Consistent with the U.S. patent laws, Genopaver shall ensure
that Genopaver Products appropriately identify Intrexon Patents. Genopaver shall provide Intrexon with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain
Intrexon’s approval thereof. Genopaver’s use of the Intrexon Trademarks and patent markings shall be subject to prior review and approval of the IPC. Genopaver acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and
agrees not to take any action inconsistent with such ownership. Genopaver covenants that it shall not 

  
 19 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Genopaver Product). From time to time during the Term, Intrexon shall have the
right to obtain from Genopaver samples of Genopaver Product sold by Genopaver or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of inspecting the quality of
such Genopaver Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.7, Intrexon shall notify the result of such inspection to Genopaver in writing
thereafter. Genopaver shall comply with reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and value of the Intrexon Trademarks. 
 4.8 Reporting Compliance. During the Term, in the event that Intrexon notifies Genopaver that Intrexon has reasonably concluded, after consultation with its outside advisors, that Intrexon will
have to consolidate Genopaver’s financial statements with its own, for so long as Intrexon reasonably believes that such consolidation is necessary, Genopaver shall comply with the following additional obligations: 

(a) Genopaver shall maintain at its principal place of business or, upon notice to Intrexon, at such other place as Genopaver shall
determine: 
 (i) a copy of Genopaver’s certificate of incorporation or organizational document and all amendments thereto,
together with executed copies of any powers of attorney pursuant to which any amendment has been executed; 
 (ii) a copy of
this Agreement; 
 (iii) a copy of Genopaver’s federal, state, and local income tax returns and reports, if any; and

 (iv) minutes of meetings of Genopaver’s board of directors and shareholders or actions by written consent in lieu
thereof, redacted as necessary by Genopaver to exclude any sensitive or confidential information that Intrexon, by operation of law or contractual stipulation, is not permitted to receive. 

(b) Genopaver shall keep its books and records consistent with US GAAP. 

(c) Intrexon at its own expense and upon reasonable notice, may examine any information it may reasonably request (including, to
the extent Genopaver has the right to provide such, the work papers of Genopaver’s internal and independent auditors) and make copies of and abstracts from the financial and operating records and books of account of Genopaver, and discuss the
affairs, finances and accounts of Genopaver with Genopaver and independent auditors of Genopaver, all at such reasonable times and as often as Intrexon or any agents or representatives of Intrexon may reasonably request. The rights granted pursuant
to this Section 4.8(c) are expressly subject to compliance by Intrexon with the safety, security and confidentiality procedures and guidelines of Genopaver, as such procedures and guidelines may be established from time to time. 

(d) As soon as available but no later than ninety (90) days after the end of


  
 20 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
each fiscal year, Genopaver shall cause to be prepared and Intrexon to be furnished with an audited balance sheet as of the last day of such fiscal year and an audited income statement, a
statement of stockholders’ equity and statement of cash flows for Genopaver for such fiscal year and notes associated with each, in each case prepared in accordance with US GAAP, together with a report of Genopaver’s independent
auditor that such statements have been prepared in accordance with US GAAP and present fairly, in all material respects, the financial position, results of operations and cash flows of Genopaver. 

(e) As soon as available but no later than forty five (45) days after the end of each calendar quarter, Genopaver shall
furnish the following to Intrexon an unaudited balance sheet as of the last day of such period, and an unaudited income statement, a statement of cash flows and a statement of stockholders’ equity for Genopaver for such period, in each case
prepared in accordance with US GAAP. 
 (f) As requested by Intrexon on no more than a quarterly basis, a certificate,
executed by the Executive Officer of Genopaver, certifying on behalf of Genopaver the following: 
 (i) Genopaver maintains
accurate books and records reflecting its assets and liabilities and maintains proper and adequate internal accounting controls that provide assurance that (1) transactions are executed with management’s authorization;
(2) transactions are recorded as necessary to permit preparation of the consolidated financial statements of Genopaver and to maintain accountability for Genopaver’s consolidated assets; (3) access to the assets of Genopaver is
permitted only in accordance with management’s authorization; (4) the reporting of assets of Genopaver is compared with existing assets at regular intervals; and (5) accounts, notes and other receivables and inventory are recorded
accurately, and proper and adequate procedures are implemented to effect the collection of accounts, notes and other receivables on a current and timely basis. 
 (ii) under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; any such controls and procedures are effective to ensure that all material information
concerning (ii) Genopaver is made known on a timely basis to those individuals responsible for the preparation of any filings that may be required to be made by Intrexon with the SEC and other public disclosure documents. 

(g) Genopaver shall promptly prepare and furnish to Intrexon any information, whether written or oral, requested by Intrexon that
is reasonably necessary for purposes of Intrexon’s ongoing compliance with applicable law. 
 4.9 Modification of
Deadlines. The parties agree that the delivery deadlines in Section 4.8 will be modified to the extent necessary to ensure that such deliverables are provided by Genopaver no less than thirty (30) days prior (inclusive of any cure
period set forth in Section 10.2(a)) to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be or become subject from time to time. Intrexon will provide Genopaver with notice as
promptly as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines or cure periods under this Section 4.9. 

  
 21 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 5 
 COMPENSATION 
 5.1 Technology Access Fee. In partial
consideration for Genopaver’s appointment as an exclusive channel collaborator in the Field and the other rights granted to Genopaver hereunder and as an access fee for commercial license rights to the Intrexon IP granted under
Section 3.1, Genopaver shall pay to Intrexon a one time cash payment of three million United States dollars ($3,000,000) (the “Technology Access Fee”). The Technology Access Fee shall be paid within ten (10) business days
by Genopaver, and the receipt of such payment by Intrexon is a condition subsequent to the effectiveness of this Agreement. 

5.2 Revenue Sharing. 
 (a) No later than thirty (30) days after each calendar quarter in which there are positive aggregate Gross Profits arising from the sale of Genopaver Products in the Field and Territory or
from the sale of Genopaver Products for Permitted Ancillary Commercial Uses, Genopaver shall pay to Intrexon a royalty equal to [*****] of such Gross Profits during that calendar quarter. Commencing with the Effective Date, in the event that there
are negative Gross Profits for a particular Genopaver Product in any calendar quarter, neither Genopaver nor Intrexon shall owe any payments hereunder with respect to such Genopaver Product. Any negative Gross Profits that results from Excess
Product Liability Costs may be carried forward to future quarters and offset against positive Gross Profits in such future quarters for the same Genopaver Product. Except as set forth in the preceding sentence, Genopaver shall not be permitted to
carry forward any negative Gross Profits to subsequent quarters. 
 (b) If Genopaver or its Affiliates commercially uses
Genopaver Products as a component of, or as a chemical intermediate in the commercial production of, derivative or other downstream products, Genopaver will pay to Intrexon, in cash, royalties at a rate of [*****] of the Gross Profits that would
have been obtainable by Genopaver or its Affiliates had the same quantities of Genopaver Product used by Genopaver and its Affiliates instead been sold in an arm’s length transaction to a Third Party. Payments under this Section 5.2(b)
will be due no later than thirty (30) days after each calendar quarter in which use occurs. 
 (c) No later than
thirty (30) days after each calendar quarter in which Genopaver or any Genopaver Affiliate receives Sublicensing Revenue, Genopaver shall pay to Intrexon [*****] of such Sublicensing Revenue. 

5.3 Method of Payment. Payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a
bank in the United States designated in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars. 
 5.4 Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter during which Gross Profits have been generated, during which


  
 22 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
Sublicensing Revenue has been received, or during which a negative Gross Profits has occurred, Genopaver shall deliver to Intrexon a written report that shall contain at a minimum for the
applicable calendar quarter: 
 (a) gross sales of each Genopaver Product on a country-by-country basis; 

(b) itemized calculation of Gross Profits, showing all applicable COGS deductions; 

(c) itemized calculation of any payment due under Section 5.2(b), including an identification of the Genopaver Product
involved, the quantity so used, the prevailing market price being used by Genopaver, and an indication of how Genopaver determined such prevailing market price; 
 (d) itemized calculation of Sublicensing Revenue; 
 (e) the amount
of any negative Gross Profits for the applicable calendar quarter, and any negative Gross Profits amount carried forward from a prior quarter and applied during the present quarter (as per Section 5.2(a)); 

(f) the amount of the payment (if any) due pursuant to each of Sections 5.2(a), 5.2(b), and 5.2(c); 

(g) the amount of taxes, if any, withheld to comply with any applicable law; and 

(h) the exchange rates used in any of the foregoing calculations. 
 For three (3) years after each sale or other commercial use of Genopaver Product, or after incurring any component item Genopaver incorporated into its calculation of Sublicensing Revenues, payments
in accord with Section 5.2(b), Gross Profits or COGS as reported to Intrexon, Genopaver shall keep (and shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales, commercial use,
or component item in sufficient detail to confirm the accuracy of the payment calculations hereunder. 
 5.5 Audits.

 (a) Upon the written request of Intrexon, Genopaver shall permit an independent certified public accounting firm
of internationally recognized standing selected by Intrexon, and reasonably acceptable to Genopaver, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable
records of Genopaver and its Affiliates to verify the accuracy and timeliness of the reports and payments made by Genopaver under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three
(3) years prior to the date of such request. The accounting firm shall disclose to both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific
details concerning any discrepancies. Such audit may not be conducted more than once in any calendar year. 

  
 23 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (b) If such accounting firm concludes that additional amounts were owed during
such period, Genopaver shall pay additional amounts, with interest from the date originally due as set forth in Section 5.7, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the underpayment
is greater than five percent (5%) of the total amount actually owed for the period audited, then Genopaver shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the
event of overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s). 
 (c) Intrexon shall (i) treat all information that it receives under this Section 5.5 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm
to enter into an acceptable confidentiality agreement with Genopaver obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to
enforce its rights under this Agreement. 
 5.6 Taxes. The Parties will cooperate in good faith to obtain the benefit of
any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Genopaver shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or
withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to Genopaver or the appropriate governmental authority
(with the assistance of Genopaver to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Genopaver of its obligation to withhold
tax, and Genopaver shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that Genopaver has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its
receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, Genopaver withholds any amount, it shall make timely payment to the proper taxing
authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment. 
 5.7 Late Payments. Any amount owed by Genopaver to Intrexon under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of
(a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 

  
 24 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 6 
 INTELLECTUAL PROPERTY 
 6.1 Ownership.

 (a) Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with
Intrexon. 
 (b) Genopaver and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries,
inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Alkaloid Program (collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed
written description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 
 (c) Intrexon shall solely own all right, title and interest in all Inventions made with, using, or otherwise incorporating Intrexon Channel Technology, together with all Patent rights and other
intellectual property rights therein (the “Channel-Related Program IP”). Genopaver hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to Intrexon. Genopaver agrees to execute such documents
and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof. 
 (d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology, whether or not patentable, that is conceived, reduced to practice
or developed by Genopaver solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of this Agreement, together with all patent rights and other intellectual
property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 
 (e)
All Information regarding Channel-Related Program IP shall be Confidential Information of Intrexon. Genopaver shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Alkaloid Program,
pursuant to which such person shall grant all rights in the Inventions to Genopaver (so that Genopaver may convey certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Alkaloid
Program. 
 6.2 Patent Prosecution. 
 (a) Intrexon shall have the sole right, but not the obligation, to (i) conduct and control the filing, prosecution and maintenance of the Intrexon Patents, and (ii) conduct and control
the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates that may be available as a result of the regulatory approval of any Genopaver Product. Notwithstanding the foregoing,
Genopaver may request that Intrexon pursue a patent for a Genopaver Product, and, if Intrexon declines to do so, then the issue shall be referred to and resolved by the IPC. At the reasonable request of Intrexon, Genopaver shall cooperate with
Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall Genopaver (i) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application,
either in the United States or elsewhere, that claims or uses or purports to claim or use or relies for support 

  
 25 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
upon an Invention owned by Intrexon, (ii) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any Confidential Information
of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or (iii) without prior approval of
the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or supplementary protection certificate, either in the United States or elsewhere, that relies upon the regulatory
approval of an Genopaver Product. 
 (b) Genopaver shall have the sole right, but not the obligation, to conduct and
control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by Genopaver or its Affiliates and not assigned to Intrexon under Section 6.1(c) (“Genopaver Program Patents”). At the reasonable
request of Genopaver, Intrexon shall cooperate with Genopaver in connection with such filing, prosecution, and maintenance, at Genopaver’s expense. 
 (c) As used in this Section, “Prosecuting Party” means Intrexon in the case of Intrexon Patents and Genopaver in the case of Genopaver Program Patents. The Prosecuting Party shall
be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Genopaver Program Patents,
as applicable. The Prosecuting Party shall: 
 (i) regularly provide the other Party in advance with reasonable information
relating to the Prosecuting Party’s prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings
and correspondence that the Prosecuting Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may, in lieu of directly
providing copies of such information to such other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

(ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided,
however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may
have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 
 (iii) consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and Genopaver
Program Patents, as applicable. 

  
 26 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 6.3 Infringement of Patents by Third Parties. 

(a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate
action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action. 
 (b) Notwithstanding the foregoing, Genopaver shall have the first right, but not the obligation,
to take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by
settlement or lawsuit or other appropriate action. If Genopaver exercises the foregoing right, Intrexon agrees to be named in any such action if required. If Genopaver fails to take the appropriate steps to enforce Product-Specific Program Patents
against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the
obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 
 (c) With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated
through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a
commercially reasonable manner against such Field Infringement, or (ii) [*****]. To the extent Genopaver shall be entitled to a share of the Recovery a set forth in Section 6.3(f), Intrexon and Genopaver shall bear the costs and expenses
of such enforcement equally. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Genopaver on such determination. For the
avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 

(d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the
enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses
will be shared equally in accordance with terms thereof). 
 (e) Genopaver shall not settle or otherwise compromise any
action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably
withheld. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Genopaver in the Field or adversely affects any Intrexon Patent with respect to the Field without
Genopaver’s prior written consent, which consent shall not be unreasonably withheld. 

  
 27 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (f) Except as otherwise agreed to by the Parties in writing, any settlements,
damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs and expenses
(if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to Section 6.3(a) that does
not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Genopaver pursuant to Section 6.3(b),
Genopaver shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as Sublicensing Revenue. In any action initiated by Intrexon or Genopaver pursuant to Section 6.3(c), the Parties shall
share the Recovery equally, and such Recovery shall not be deemed to constitute Sublicensing Revenue. 
 (g) Genopaver
shall promptly notify Intrexon of any suspected, alleged, threatened, or actual Infringement of which it becomes aware, and Intrexon shall promptly notify Genopaver of any suspected, alleged, threatened, or actual Field Infringement of which it
becomes aware. 
 ARTICLE 7 
 CONFIDENTIALITY 
 7.1 Confidentiality. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for
in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a) was already known to the receiving Party and can be demonstrated by written records, other than under an obligation of
confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or otherwise
part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the
public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such
information to others; or 
 (e) was independently discovered or developed by the receiving Party without the use of
Confidential Information belonging to the disclosing Party, as documented by the receiving Party’s written records. 

  
 28 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 The foregoing non-use and non-disclosure obligation shall continue
(i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 

7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential
Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(a) complying with applicable laws or regulations or valid court orders, provided that the Party making such disclosure
provides the other Party with reasonable prior written notice of such request or demand for disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure
and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or for which the order was issued; 
 (b) to regulatory authorities in order to seek or obtain approval to conduct regulatory trials, or to gain regulatory approval, of Genopaver Products or any products being developed by Intrexon or
its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with reasonable opportunity to review any such disclosure in advance and to suggest redactions or other
means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions; 
 (c) disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the confidentiality of such information, provided that such disclosure is used
solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 
 (d) disclosure on a
need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and

 (e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators
who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7. 
 7.3 Publicity; Publications. Following the Effective Date, the Parties will consult to consider, and, if mutually desired, draft and release, a public announcement of the execution of this
Agreementsubstantially in the form of a press release, which form shall be mutually agreed to by the Parties. Each Party will provide the other Party with the opportunity to review and comment, prior to submission or presentation, on external
reports, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer to the Alkaloid Program, Genopaver Products or programs that are approved by the JSC.
For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar days for review of the proposed submission or presentation. In the case of a Form 8-K filing, such shall be
provided to Intrexon 

  
 29 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
by Genopaver as soon as practicable prior to filing. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the report or
manuscript. The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or
presentations if necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. 

7.4 Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party,
subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point
during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably
available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider
and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such
comments. 
 7.5 Proprietary Information and Operational Audits. 

(a) For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of
Article 4, and the confidentiality obligations under Article 7, Genopaver acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect Genopaver’s facilities and
(ii) inspect all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to Genopaver.
Genopaver will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 
 (b) For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the confidentiality obligations under Article 7, Intrexon acknowledges that Genopaver authorized
representative(s), during regular business hours may (i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five
(5) business days written notice from Genopaver to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Genopaver for the aforementioned compliance review. 

(c) In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to Genopaver
hereunder, Intrexon from time-to-time, but no more than quarterly, may request that Genopaver confirm the status of the Intrexon Materials at Genopaver (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when)
as well as any amounts returned to Intrexon or destroyed). Within ten (10) business days of Genopaver’s receipt of any such written request, Genopaver shall provide the written report to Intrexon. 

  
 30 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an
agreement with its other licensees and channel partners or collaborators to enable Genopaver to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval
to conduct regulatory trials, or to gain regulatory approval of, Genopaver Products, in a manner consistent with the provisions of Section 7.2(b). 
 ARTICLE 8 
 REPRESENTATIONS AND
WARRANTIES 
 8.1 Representations and Warranties of Genopaver. Genopaver hereby represents and
warrants to Intrexon that, as of the Effective Date: 
 (a) Corporate Power. Genopaver is duly organized and validly
existing under the laws of Delaware and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Genopaver is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Genopaver’s
behalf has been duly authorized to do so by all requisite corporate action. 
 (c) Binding Agreement. This Agreement is a
legal and valid obligation binding upon Genopaver and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting
creditors’ rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Genopaver does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Genopaver is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the
validity of this Agreement. 
 8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and warrants to
Genopaver that, as of the Effective Date: 
 (a) Corporate Power. Intrexon is duly organized and validly existing under
the laws of Virginia and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf
has been duly authorized to do so by all requisite corporate action. 

  
 31 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (c) Binding Agreement. This Agreement is a legal and valid obligation binding
upon Intrexon and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject
to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement.

 (d) Additional Intellectual Property Representations. 

(i) Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to Genopaver with
respect to the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents and Intrexon Know-How existing as of the
Effective Date constitute all of the Patents and Know-How Controlled by Intrexon as of such date that are necessary for the development, manufacture and Commercialization of Genopaver Products; 

(iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right or license, to any Third Party under the Intrexon
IP that conflicts with the rights or licenses granted or to be granted to Genopaver hereunder; 
 (iv) There is no pending
litigation, and Intrexon has not received any written notice of any claims or litigation, seeking to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s rights therein; 

(v) None of the Intrexon Patents is subject to any pending re-examination, opposition, interference or litigation proceedings;

 (vi) All of the Intrexon Patents have been filed and prosecuted in accordance with all applicable laws and have been
maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (vii)
Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of Intrexon IP, providing Intrexon, to the extent permitted by law, with
title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons, during the period of employment or contract by Intrexon (except
where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Genopaver herein), and Intrexon is not aware that any of its employees or consultants is in material violation thereof;


  
 32 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (viii) To Intrexon’s knowledge, there is no infringement, misappropriation or
violation by Third Parties of any Intrexon Channel Technology or Intrexon IP in the Field; 
 (ix) There is no pending or, to
Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the
use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written notice of such claim; 
 (x)
To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer (A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee
while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel Technology in the Field; 
 (xi) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or
unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or
scope of any such Intrexon Patents; and 
 (xii) Except as otherwise disclosed in writing to Genopaver, Intrexon: (A) is
in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or
disposal of any product that is under development, manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or
other correspondence or notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the
aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not
in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the
FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA
or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or


  
 33 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and
has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated,
conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, letters to customers, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or
violation and, to Intrexon’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. 

except, in each of (ix) through (xii), for any instances which would not, individually or in the aggregate, result in a material adverse effect on
the rights granted to Genopaver hereunder or Intrexon’s ability to perform its obligations hereunder. 
 8.3 Warranty
Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 9 

INDEMNIFICATION 
 9.1 Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend Genopaver and its Affiliates and their respective directors, officers, employees, and agents (collectively,
the “Genopaver Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”) resulting from any
claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from (a) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or their
respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than Genopaver) or sublicensees; or (c) breach by Intrexon of any
representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the Genopaver Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful
misconduct of Genopaver or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by Genopaver of a representation, warranty, or covenant of this Agreement. 

  
 34 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 9.2 Indemnification by Genopaver. Genopaver agrees to indemnify, hold harmless,
and defend Intrexon, its Affiliates and Third Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the
Effective Date, to the extent required by the relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following:
(a) the gross negligence or willful misconduct of Genopaver or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of Genopaver or its
Affiliates, licensees, or sublicensees; (c) breach by Genopaver of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport,
distribution, sale or other disposition of any Genopaver Product by or on behalf of Genopaver or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, Genopaver shall not have any obligation to indemnify the Intrexon Indemnitees
to the extent that a Claim arises from (i) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of
this Agreement. 
 9.3 Product Liability Claims. Notwithstanding the provisions of Section 9.2, any Losses arising
out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or Commercialization of any Genopaver Products for
use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”), shall be paid by [*****], except to the
extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees, or any of the respective officers, directors, employees and agents of each of
the foregoing entities, in the performance of obligations or exercise of rights under this Agreement. 
 9.4 Control of
Defense. As a condition precedent to any indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification,
promptly after learning of such Claim. If such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the
indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such
Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party
shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified
Party under this Agreement, unless the indemnified Party otherwise agrees in writing. 

  
 35 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 9.5 Insurance. Immediately prior to, and during marketing of Genopaver Products,
Genopaver shall maintain in effect and good standing a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately prior to, and during the conduct of any regulatory trials,
Genopaver shall maintain in effect and good standing a regulatory trials liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, Genopaver shall
provide Intrexon with all details regarding such policies, including without limitation copies of the applicable liability insurance contracts. Genopaver shall use reasonable efforts to include Intrexon as an additional insured on any such policies.

 ARTICLE 10 
 TERM; TERMINATION 
 10.1 Term. The
term of this Agreement shall commence upon the Effective Date and shall continue until terminated pursuant to Section 10.2 or 10.3 (the “Term”). 
 10.2 Termination for Material Breach; Termination under Section 4.4(b) 

(a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other Party
commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach; provided, however, that if Genopaver commits any breach of
the provisions of Section 4.9 of this Agreement, Intrexon shall have the right to terminate this Agreement if Genopaver fails after notice from Intrexon to cure such breach within thirty (30) days following written notice thereof.

 (b) Intrexon shall have the right to terminate this Agreement, at its sole discretion, the Technology Access Fee has
not been paid in accordance with Section 5.1. 
 (c) Intrexon shall have the right to terminate this Agreement under
the circumstances set forth in Section 4.4(b) upon written notice to Genopaver, such termination to become effective sixty (60) days following such written notice unless Genopaver remedies the circumstances giving rise to such termination
within such sixty (60) day period. 
 (d) Intrexon shall have the right to terminate this Agreement should Genopaver
execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to Genopaver and becoming effective immediately upon such written notice.

 10.3 Termination by Genopaver. Genopaver shall have the right to voluntarily terminate this Agreement in its entirety
upon ninety (90) days written notice to Intrexon at any time. 

  
 36 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 10.4 Effect of Termination. In the event of termination of this Agreement
pursuant to Section 10.2 or Section 10.3, the following shall apply: 
 (a) Retained Products. Genopaver shall
be permitted to continue the development and Commercialization in the Field of any product resulting from the Alkaloid Program that, at the time of termination, satisfies at least one of the following criteria (a “Retained
Product”): 
 (i) the particular product is an Genopaver Product that is being sold by Genopaver (or, as may be
permitted under this Agreement, its Affiliates and, if applicable, (sub)licensees) triggering profit sharing payments therefor under Section 5.2(a) or (b) of this Agreement, 

(ii) the particular product is an Genopaver Product that has received regulatory approval, 

(iii) the particular product is an Genopaver Product that is the subject of an application for regulatory approval in the Field that is
pending before the applicable regulatory authority, or 
 (iv) the particular product is a Genopaver Product that has been
adopted for commercial scale up by the JSC, or that has otherwise acheived under the Alkaloid Program a benchmark production rate pre-established by the JSC for advancement of that product to commercial scale up or pilot production, which benchmark
(A) takes into account relevant commercial and technical factors with respect to the product in question and (B) the achievement of which would be accepted in the industry as being reasonably indicative of such product being suitable for
such advancement. 
 Such right to continue development and Commercialization shall be subject to Genopaver’s full compliance with the
payment provisions in Article 5, a continuing obligation for Genopaver to use in accord with Section 4.4(a) to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive termination. 

(b) Termination of Licenses. Except as necessary for Genopaver to continue to obtain regulatory approval for, develop, use,
manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Genopaver under this Agreement shall terminate and shall revert to Intrexon without further action
by either Intrexon or Genopaver. Genopaver’s license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 

(c) Reverted Products. All Genopaver Products other than the Retained Products shall be referred to herein as the
“Reverted Products.” Genopaver shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Genopaver shall not
use or practice, nor shall it cause or authorize any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. Genopaver shall immediately discontinue
making any representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 

  
 37 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (d) Intrexon Materials. Genopaver shall promptly return, or at Intrexon’s
request, destroy, any Intrexon Materials in Genopaver’s possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and Commercialization of
the Retained Products in the Field. 
 (e) Licenses to Intrexon. Genopaver is automatically deemed to grant to Intrexon a
worldwide, fully paid, royalty-free, exclusive (even as to Genopaver and its Affiliates), irrevocable, license (with full rights to sublicense) under the Genopaver Termination IP, to make, have made, import, use, offer for sale and sell Reverted
Products and to use the Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Genopaver in Reverted Products pursuant to Section 10.4(c). The Parties shall also take
such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. 
 (f) Regulatory Filings. Genopaver shall promptly assign to Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted
Products. Genopaver shall also take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and
regulatory filings that relate both to Reverted Products and other products, Genopaver shall provide copies of the portions of such regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining
the benefits of such regulatory approvals with respect to the Reverted Products. 
 (g) Data Disclosure. Genopaver shall
provide to Intrexon copies of the relevant portions of all material reports and data, including regulatory trial data and reports, obtained or generated by or on behalf of Genopaver or its Affiliates to the extent that they relate to Reverted
Products, within sixty (60) days of such termination unless otherwise agreed, and Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so.

 (h) Third Party Licenses. At Intrexon’s written request, Genopaver shall promptly provide to Intrexon copies of
all Third Party agreements under which Genopaver or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or Commercialization of the Reverted
Products. At Intrexon’s written request such that Intrexon may Commercialize the Reverted Products, Genopaver shall promptly work with Intrexon to either, as appropriate (i) assign to Intrexon the Third Party agreement(s), or
(ii) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third Party agreements.
Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Genopaver and
Genopaver shall not make such assignment or grant such sublicense (or cause it to be made or granted). 

  
 38 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 (i) Remaining Materials. At the request of Intrexon, Genopaver shall transfer to
Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of Genopaver or its Affiliates. Genopaver shall transfer to Intrexon all such quantities of Reverted Products without charge, except that
Intrexon shall pay the reasonable costs of processing and shipping. 
 (j) Third Party Vendors. At Intrexon’s
request, Genopaver shall promptly provide to Intrexon copies of all agreements between Genopaver or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the
Territory. At Intrexon’s request, Genopaver shall promptly: (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such
agreements to Intrexon, and (ii) with respect to all other such Third Party agreements, Genopaver shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Genopaver shall be liable for any costs associated
with assigning a Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to Genopaver’s breach. For the avoidance of doubt, Intrexon shall have no
obligation to assume any of Genopaver’s obligations under any Third Party agreement. 
 (k) Commercialization.
Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Genopaver, to take any such actions in connection with such activities as
Intrexon (or its designee), at its discretion, deems appropriate. 
 (l) Confidential Information. Each Party shall
promptly return, or at the other Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain
(i) a single copy of each item of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party
that is maintained as archive copies on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained
Products (in the case of Genopaver) or Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information
retained in accordance with this Section 10.4(l). 
 10.5 Surviving Obligations. Termination or expiration of this
Agreement shall not affect any rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of Genopaver to pay any amount which became due and payable under the terms and
conditions of this Agreement prior to expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b), 5.4, 5.6, 6.1, 6.2 (with
subsection (c) surviving only to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or Commercialized at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5;
Articles 9, 11, and 12; and any relevant definitions in Article 1. Further, Article 7 and Sections 4.4, 5.2 through 5.7, and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products. 

  
 39 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 11 

DISPUTE RESOLUTION 
 11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and
without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement (other than disputes arising from a Committee), including,
without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by written notice, the Parties agree to meet and
discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written
request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved solely in accordance
with Section 2.4. 
 11.2 Arbitration. Any dispute, controversy, difference or claim which may arise between the
Parties and not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance,
application or termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Sections 11.9 and 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of the
thirty (30) day period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in the state where the other Party’s principal
office is located (or some other place as may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator
shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology industries, and shall have some
experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator meeting the
foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the
case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the resolution for the matter at issue
(the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within
fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other


  
 40 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
Party’s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as
expressly permitted in this Section 11.2; provided that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms.
Within sixty (60) days after the arbitrator’s appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying
and agreed principles set forth in this Agreement. The decision of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of
Proposed Terms, and may not combine elements of both Proposed Terms or award any other relief or take any other action. 

11.3 Governing Law. This Agreement shall be governed by and construed under the substantive laws of the State of New York,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

11.4 Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set forth above under
Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party.
Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final
award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of
the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award
consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages. The only damages
recoverable under this Agreement are direct compensatory damages. 
 11.5 Costs. Each Party shall bear its own legal
fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration. 
 11.6
Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or
other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that
a material breach by either Party of its obligations in Section 3.5 or Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies
otherwise available at law, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5 or Article 7, and without further proof


  
 41 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to, both
interim and permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall
otherwise limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 
 11.7 Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each Party’s Confidential Information.
Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without prior written consent of the other Party. The existence of any
dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or as otherwise required by applicable law. 

11.8 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this
Agreement for any reason. 
 11.9 Jurisdiction. For the purposes of this Article 11, the Parties acknowledge their
diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this
Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts. 
 11.10 Patent
Disputes. Notwithstanding any other provisions of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall
be submitted to a court of competent jurisdiction in the country in which such Patent was filed or granted. 
 ARTICLE 12

 GENERAL PROVISIONS 

12.1 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the
other or any other trade name or trademark of the other in connection with the performance of this Agreement, except that (a) either Party may use the name of the other Party as required by law or regulation and in press releases accompanying
quarterly and annual earnings reports approved by the issuer’s Board of Directors, and (b) Genopaver may use the Intrexon Trademarks in accord with licenses and restrictions set forth herein. 

12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH 

  
 42 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR
BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 
 12.3 Independent Parties. The Parties are not employees or legal
representatives of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a
joint venture, partnership, or business organization of any kind. 
 12.4 Notice. All notices, including notices of
address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms
receipt of such transmission with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage
prepaid, return receipt requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Chief Operating Officer
 Fax: (301) 556-9901

		
	with a copy to:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Legal Department
 Fax: (301) 556-9902

		
	If to Genopaver:	  	 Genopaver, LLC
 2875 South
Ocean Boulevard
 Suite 214
 Palm Beach,
FL 33480
 Attention: Legal Department

Phone: (561) 328-6459
 Fax: (561)
355-0627


 12.5 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 

  
 43 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 12.6 Waiver. Any waiver (express or implied) by either Party of any breach of
this Agreement shall not constitute a waiver of any other or subsequent breach. 
 12.7 Entire Agreement; Amendment. This
Agreement, including any exhibits attached hereto, constitute the entire, final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of
this Agreement (including any prior confidentiality agreement between the Parties). All information of Intrexon or Genopaver to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be
maintained as Confidential Information by such other Party under the obligations set forth in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party.

 12.8 Non-assignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations
under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent
(a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets, provided
that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators
and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization, or similar transaction,
or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual
property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed to the other Party under this Agreement. 

12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its obligations under this
Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes, governmental
regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11
Non-Solicitation. During the Term and for a period of one (1) year following the end of the Term, neither Genopaver nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment
with, or hire any employee of 

  
 44 










 EXECUTION COPY 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
  

 
the other Party or an individual who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party.
General employment solicitations or advertisements shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement. 
 12.12 Legal Compliance. The Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 

12.13 Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of
electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart. 

[Remainder of page intentionally left blank.] 

  
 45 









 EXECUTION COPY 

IN WITNESS WHEREOF, the Parties hereto have duly executed this Exclusive Channel
Collaboration Agreement. 
  

							
	 INTREXON CORPORATION
	  	GENOPAVER, LLC
				
	By:	 	 /s/ Krish S. Krishnan
	  	By:	 	 /s/ Theodore J. Fisher



							
				
	Name:	 	 Krish S. Krishnan
	  	Name:	 	 Theodore J. Fisher



							
				
	Title:	 	 Chief Operating Officer
	  	Title:	 	 Secretary


  

	5	

 SIGNATURE PAGE FOR EXCLUSIVE
CHANNEL COLLABORATION AGREEMENT 

  
 46